NeOnc Technologies (NTHI) said Monday it expects full enrollment in a phase 2a trial for its therapeutic candidate NEO100-01 by September, with just six patients remaining to reach the 25-patient target.
The trial is evaluating NEO100, which is intended for the treatment of malignant gliomas, particularly IDH1 mutant Grade III and IV astrocytomas. The read-out for the trial's data is expected early next year, the company said.
The drug candidate has been granted orphan drug and fast-track status by the US Food and Drug Administration, according to the company.
Price: 8.64, Change: -0.27, Percent Change: -3.03
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.